However, practical concerns must be addressed if the efforts of clinical trial funders, journals, and secondary users of clinical trial data to promote data sharing are to succeed.
Clinical trials have flourished within the pharmaceutical field, and the drug industry is the main financer and user of trials.
Future users of clinical trial data who identify findings that they consider to have clinical relevance should inform the primary study investigator of these findings, but must understand that all decisions related to notifying research participants of incidental or research genetic results reside with the primary study investigators and their IRBs.
TechCrunch understands, however, that those who get invited can bring in another three users to trial the service, regardless of country or carrier.
Survey participation requests were sent to 709 unique clinical trialists (fig 1); 26 were subsequently excluded from our study population because contact information was invalid (n=18), technical difficulties prevented the author from accessing the survey (n=4), or the author was a secondary user of clinical trial data generated by another research group (n=4).
In fact, James Barksdale, Netscape C.E.O., testified that Netscape had between 40 and 70 million users at the time of trial, and internal Netscape documents from October of 1997, a year before the commencement of trial, estimate that Navigator's installed base was 65 million, up from 40 million the year before.
But Apple has come out swinging, declaring that only 21% of trial users have opted out. .
The watchdog noted that "there is some dissatisfaction with these services among corporate users of the market".The trial began in Paris of Jérôme Kerviel, a former trader at Société Générale who is accused of a breach of trust and forgery in racking up unhedged bets that ultimately led in January 2008 to a €4.9 billion loss (then worth $7.2 billion) at the French bank.
The company also reportedly enjoyed Beats' ability to convert free trial users of its service to paid subscribers, according to a recent Bloomberg report.
Even if clinical researchers could match the demographics of study populations to those of the likely users of these medicines, no group of trial volunteers could ever match the extraordinary biological diversity of the drugs' eventual consumers.
